Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
July 11, 2024 12:00 ET
|
Revolution Medicines, Inc.
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in...
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
July 08, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Quanta Announces Dosing of First Patient in Phase 1/1b Clinical Trial of QTX3046, an Oral KRASᴳ¹²ᴰ-Selective Dual-State Allosteric Inhibitor, and Other Program Updates
June 27, 2024 09:00 ET
|
Quanta Therapeutics, Inc.
Quanta is advancing 2 clinical trials from its pipeline of KRAS G12D-focused drug candidates, as monotherapy and combination with EGFR inhibitors
Global KRAS Inhibitors Market & Clinical Trials Future Market Outlook 2030: 2 Approved KRAS Inhibitors and 90+ Drugs KRAS Inhibitors in Clinical Trials
June 20, 2024 06:59 ET
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030" report has been added to ResearchAndMarkets.com's offering. With the...
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Analysis of the KRAS Mutant Cancer Pipeline, 2024: Emerging Therapies, Key Players, Unmet Needs and More
May 30, 2024 04:30 ET
|
Research and Markets
Dublin, May 30, 2024 (GLOBE NEWSWIRE) -- The "KRAS Mutant Cancer - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report outlays comprehensive...
[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 20, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, May 20, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Colorectal Cancer Market Size, Trends and Insights By Type of Treatment (Surgery,...
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
May 15, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, May 15, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
May 08, 2024 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
May 02, 2024 16:05 ET
|
Cardiff Oncology, Inc.
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated...